Last edition
News about
Dr. Reddy's Signs USD 370 Million Licensing Deal for Eftilagimod Alfa
Dr. Reddy’s Laboratories has entered into an exclusive licensing agreement with Australian biotechnology company Immutep to commercialise its investigational immunotherapy, Eftilagimod Alfa (Efti), across markets outside North America, Europe, Japan and Greater China.
Boehringer Advances First-in-Class Triple-Agonist Peptide for Obesity and CRM Disorders
Boehringer Ingelheim has announced the advancement of BI 3034701, a long-acting, potential first-in-class triple-agonist peptide being developed for the treatment of obesity. The progress marks a key milestone in the company’s strategy to tackle the global burden of obesity and its interlinked cardiovascular, renal, and metabolic (CRM) complications.
Convergen Raises USD 10 Million Seed Funding to Advance TrimTAC Platform
Convergen has raised USD 10 million in seed funding from Qiming Venture Partners to speed up development of its TrimTAC platform—novel TRIM21-based bifunctional degraders—and advance its early pipeline targeting neurodegenerative and other high-need diseases.
Ouro Medicines Receives US FDA ODD for Gamgertamig (OM336) for Immune Thrombocytopenia
Ouro Medicines has secured a second ODD from the FDA for gamgertamig (OM336), this time for immune thrombocytopenia (ITP), following an earlier designation for autoimmune hemolytic anemia (AIHA). It comes as the company completes dosing in the first cohort of its global basket trial in autoimmune cytopenias.
China Adds Leqembi to Innovative Drug Insurance List
BioArctic’s partner Eisai said Leqembi has been added to China’s new Commercial Insurance Innovative Drug List, a move by the NHSA that broadens access to the Alzheimer’s therapy for patients in the early stages of the disease.
AsymBio Begins Operations at Fengxian Base to Boost Global CDMO Capacity
AsymBio has commenced commercial operations at its 130,000-square-metre Fengxian base, adding a major hub to its global CDMO network alongside its Shanghai Jinshan and Zhangjiang facilities. The new site is built to offer flexible, scalable support across all clinical phases, delivering customised CDMO solutions.
HUTCHMED Gains Wider NRDL Coverage and First Commercial Insurance Listing in China
Effective January 1, 2026, HUTCHMED will see expanded NRDL coverage for ELUNATE, ORPATHYS and SULANDA, while TAZVERIK has been added to China’s first National Commercial Health Insurance Innovative Drug List, marking its entry into commercial insurance coverage.
Immix Biopharma Prices USD 100 Million Stock and Pre-Funded Warrant Offering
Immix Biopharma has priced its USD 100 million offering of common stock and pre-funded warrants, with plans to use the proceeds—alongside existing cash reserves—to advance the development of NXC-201 and support working capital and general corporate needs.
CLINUVEL Grows Singapore RD&I Hub to Advance Peptide Innovation
CLINUVEL is expanding its VALLAURIX Research, Development & Innovation Centre in Singapore to strengthen its work on next-generation peptide therapies. The five-year, EDB-supported investment will enhance facilities, accelerate development of liquid long-acting drug delivery platforms, and allow RD&I teams to advance late-stage programmes.
Viatris to Receive USD 400 Million in Cash and USD 415 Million in Equity Shares of Biocon
Viatris is set to receive USD 400 million in cash and USD 415 million in Biocon equity shares as part of a revised agreement, accelerating the end of non-compete restrictions in the biosimilars space and enabling both companies to pursue expanded market opportunities.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy